Extended treatment of abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis

The analysis of our data demonstrates that abrocitinib may be an effective therapeutic option in the management of CAD. IL-13 and CCL-4 might be the core effective factors after the therapy.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-02-04
DOI
https://doi.org/10.3389/fmed.2026.1742273
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Extended treatment of abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis

Lanhai Zhong, Naiyu Lin, Liangzi Liang, Lu Tang et al.
Frontiers in Medicine
Dermatology and Skin Diseases
article

Extended treatment of abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis

Lanhai Zhong, Naiyu Lin, Liangzi Liang, Lu Tang, Jiande Han
article en

Abstract

The analysis of our data demonstrates that abrocitinib may be an effective therapeutic option in the management of CAD. IL-13 and CCL-4 might be the core effective factors after the therapy.

Frontiers in MedicineVol. 13
Sun Yat-sen University (CN), The First Affiliated Hospital, Sun Yat-sen University (CN)
National Natural Science Foundation of China
Good health and well-being
Openalex Percentile: Top 68%
Dermatology and Skin Diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.